StreetInsider.com News Articles

NEXGEL announces $15 million cash deal for regenerative biomaterial portfolio

Thu, 12 Mar 2026 08:45:38 -0400

NEXGEL Inc. (NASDAQ: NXGL) announced the consideration terms for its agreement to license and acquire a portfolio of regenerative biomaterial products from Celularity Inc. (NASDAQ: CELU). The deal structure includes a $15 million upfront cash payment and potential milestone payments of up to $20 million based on net sales targets.

The portfolio consists of six commercial-stage products focused on tendon repair, skin grafts, and bone growth applications. These products have over a decade of clinical use and established insurance reimbursement pathways, according to the company's statement.

NEXGEL expects the transaction to approximately triple its annual revenue to about $35 million and projects

NEXGEL announces $15 million cash deal for regenerative biomaterial portfolio

Thu, 12 Mar 2026 08:45:38 -0400

NEXGEL expects the transaction to approximately triple its annual revenue to about $35 million and projects

Celularity reaffirms NEXGEL partnership for biomaterials commercialization

Thu, 12 Mar 2026 08:32:51 -0400

Celularity Inc. (NASDAQ: CELU) restated its strategic commercialization partnership with NEXGEL Inc. (NASDAQ: NXGL) to develop and market placental-derived biomaterials, according to a company statement.

The partnership includes six established commercial products: Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex, which are used in wound care, orthopedics and other medical applications. Three pipeline programs called SPARK, FUSE and ORCHID are also part of the licensing agreement and are pursuing 510(k) medical device regulatory pathways.

Celularity will serve as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey. The transaction is expected to close by April

Celularity reaffirms NEXGEL partnership for biomaterials commercialization

Thu, 12 Mar 2026 08:32:51 -0400

Celularity will serve as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey. The transaction is expected to close by April

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Thu, 12 Mar 2026 08:30:00 -0400

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.
Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.
Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics.